Overview

The journey of drug discovery commences with a deep understanding of patient and healthcare professional needs. Our researchers prioritize the identification of new medications that bring tangible value to patients, coupled with a comprehensive understanding of diseases from diverse perspectives. 

 

Drawing on scientific insights validated through basic research, we pinpoint targets and concepts for innovative medications. These findings form the foundation for the development of drug candidates, the building blocks for new medicines, through exploratory research. Only products that have shown safety and efficacy in the preclinical phase can then progress to the clinical development phase, where their efficacy in humans is evaluated.

 

Our focus in drug discovery is to streamline the process from basic research to early Phase II studies, ensuring that efficacy in humans aligns seamlessly with the concept, while gathering comprehensive, science-based data.

Since our inception, we have achieved significant results leveraging our extensive expertise in small molecule drug discovery, particularly targeting ion channels. Our primary research endeavors have centered on drug discovery within the domains of pain management and gastrointestinal diseases. Given the pivotal role of ion channels in various pathological conditions, they represent a formidable yet promising area of focus for us. To address these complexities, we have embraced cutting-edge protein structure analysis and informatics technologies.

 

While small molecules have historically dominated the pharmaceutical landscape, recent trends show a growing emphasis on biopharmaceuticals, such as antibodies, as well as on regenerative medicine and gene therapy. This diversification in "drug modalities" has broadened the scope of development, enabling interventions for previously challenging drug targets.  Consequently, this paradigm shift is facilitating the development of new medications for diseases that lacked effective treatments in the past.

 

We are dedicated to refining our established technologies and expertise, honed through years of development.  Simultaneously, we are initiating a new phase of innovation integrating new drug discovery technologies into our processes. This initiative aims to broaden the spectrum of diseases we address, empowering us to develop products targeting a wide array of diseases and drug targets.

Recent years have witnessed an unprecedented advancement in drug discovery technologies. To uphold our standing as an innovator in this field, it is crucial that we not only enhance our existing technologies but also integrate state-of-the-art innovations and insights from external sources.

 

We foster partnerships not only with established pharmaceutical companies, but also through joint research initiatives with academia, startups, and venture firms renowned for their pioneering drug discovery technologies. This strategy is instrumental in establishing a next-generation drug discovery value chain which leverages the strengths of each party.